# Nepafenac Once Daily for Macular Edema - Study 2

Study · id `cardio:ct-nct01872611` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01872611](<https://clinicaltrials.gov/study/NCT01872611>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01872611

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 819 participants.

## Technical summary

Registry record NCT01872611. Randomized; double masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2015-05 (actual). Results posted on 2016-08-02.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 819 participants (enrolled count; ClinicalTrials.gov record NCT01872611, source copy `cardio:ctgov-nct01872611-2016-08-02`, retrieved 2026-10-26)
- Start date: 2013-06 (registry gives no type) (ClinicalTrials.gov record NCT01872611, source copy `cardio:ctgov-nct01872611-2016-08-02`, retrieved 2026-10-26)
- Primary completion: 2015-05 (actual) (ClinicalTrials.gov record NCT01872611, source copy `cardio:ctgov-nct01872611-2016-08-02`, retrieved 2026-10-26)
- Completion: 2015-05 (actual) (ClinicalTrials.gov record NCT01872611, source copy `cardio:ctgov-nct01872611-2016-08-02`, retrieved 2026-10-26)
- Results first posted: 2016-08-02 (ClinicalTrials.gov record NCT01872611, source copy `cardio:ctgov-nct01872611-2016-08-02`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01872611-2016-08-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Nepafenac Once Daily for Macular Edema - Study 2
- Condition: Non-Proliferative Diabetic Retinopathy
- Condition: Cataract
- Intervention (Drug): Nepafenac Ophthalmic Suspension, 0.3%
- Intervention (Other): Vehicle
- Intervention (Drug): Prednisolone acetate
- Lead sponsor: Alcon Research
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 477227eb6de547bda9093d8e6ae0d2d072b102e8dc87b56eb6c2a6254807bde0
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
